Innovative Device Enhances Chemotherapy Assessment in Pancreatic Cancer

A promising approach using implantable microdevices allows real-time evaluation of chemotherapy responses in pancreatic ductal adenocarcinoma (PDAC).

• In a study with mouse models, the device enabled localized delivery of chemotherapy agents and real-time monitoring of tumor response.
• Significant reductions in tumor cell proliferation were observed after treatment, indicating drug-specific effects.

This method could advance precision medicine by guiding intra-operative decisions based on individual tumor responses.

• The strongest markers of treatment effect were seen 24 hours post-implantation, emphasizing the importance of timing in therapeutic assessment.